Generic Veterinary Drugs: Which Dog and Cat Medicines Actually Have FDA Generics
An empirical analysis of FDA Green Book data — which companion animal drugs have approved generics (ANADAs), why top brands lack them, and formulary decision rules.
When a veterinary practice owner or medical director looks at clinic drug expenditures, a recurring question arises: "Why are so few of our top-dispensed companion animal pharmaceuticals available as FDA-approved generics?"
While human medicine enjoys a generic substitution rate exceeding 90%, the companion animal pharmaceutical market operates under very different dynamics. While veterinary generic drugs (approved via the Abbreviated New Animal Drug Application, or ANADA, pathway) offer identical active ingredients, dosage forms, and bioequivalence to pioneer brand-name drugs at lower cost, their availability across dog and cat therapeutics remains surprisingly concentrated in older molecules.
Using an empirical analysis of the U.S. Food and Drug Administration (FDA) Green Book database (snapshot dated July 25, 2026, comprising 2,427 application records), this guide breaks down which companion animal molecules have approved generics today, why the highest-revenue veterinary brands have zero generic competition, and how clinic teams should navigate formulary decisions.
Fast Answer: The Current State of Veterinary Generics
If you are evaluating formulary options or explaining pet medication costs to owners:
- Overall Generic Share: In the FDA Green Book register (July 2026), out of 1,749 approved animal drug applications, 521 (29.8%) are generic ANADAs, while 1,221 are pioneer NADAs and 7 are conditional CNADAs.
- Companion Animal Market: Restricting the dataset to dog- and cat-labeled products, 175 out of 650 approved applications (26.9%) are generics.
- Molecule Availability: Across 261 distinct active ingredients approved for dogs and cats, only 69 (26.4%) have at least one FDA-approved generic. The remaining 192 active ingredients have pioneer approvals but zero approved generic alternatives.
- Where Generics Cluster: Generics are heavily concentrated in mature, legacy molecules such as carprofen (19 approved generic applications), enrofloxacin (13), and meloxicam (11).
- Where Generics Are Absent: Major modern blockbusters—including oclacitinib (Apoquel), grapiprant (Galliprant), bedinvetmab (Librela), frunevetmab (Solensia), and the isoxazoline parasiticide class (Simparica, Bravecto, NexGard, Credelio)—have zero approved generic applications.
- FDA Approval vs. Market Launch: An approved ANADA does not automatically mean the product is on distributor shelves. For example, FDA approved the first generic pimobendan in April 2024, but commercial market launch occurred in June 2026—a two-year lag.
What Does an FDA-Approved Generic (ANADA) Require?
Enacted by Congress on November 16, 1988, the Generic Animal Drug and Patent Term Restoration Act (GADPTRA) established the statutory framework for generic animal drugs in the United States.
[Pioneer New Animal Drug (NADA)]
│
Requires Full Safety & Effectiveness Studies
(Target Animal Safety, Clinical Efficacy, CMC)
│
[Patent / Exclusivity Expiration]
│
[Abbreviated New Animal Drug Application]
(ANADA)
│
┌─────────────────────────────┼─────────────────────────────┐
│ │ │
Same Active Ingredient Demonstrated Bioequivalence Identical Labeling & CMCs
& Concentration (In Vivo or Biowaiver) (Quality & Stability)
To gain FDA approval via an ANADA, a generic animal drug must demonstrate:
- Same Active Ingredient: Must contain the identical active pharmaceutical ingredient (API) at the same strength and concentration as the pioneer Reference Listed New Animal Drug (RLNAD).
- Same Route and Dosage Form: Must be formulated in the same physical dosage form (e.g., tablet, chewable tablet, oral solution, injectable) for the same administration route.
- Bioequivalence: Must demonstrate that the rate and extent of absorption of the active ingredient do not significantly differ from the pioneer drug when administered at the same molar dose under similar experimental conditions.
- Identical Labeling: The generic drug labeling must be identical to the pioneer drug labeling in indications, dosages, warnings, and contraindications (except for trade name, logo, and manufacturer details).
- Manufacturing Rigor: Must comply with FDA Current Good Manufacturing Practice (cGMP) regulations and stability testing standards.
Crucially, GADPTRA exempts generic sponsors from repeating expensive target-animal safety and clinical effectiveness trials. To learn more about how pioneer animal drugs are evaluated, see our companion guide on how the FDA veterinary drug approval process works.
Empirical Market Breakdown: What the Green Book Data Reveals
Analyzing the FDA Green Book database provides clear quantitative insights into how generic animal drugs are distributed across companion animal medicine.
1. Market Composition by Application Type
In the July 2026 Green Book snapshot, 2,427 total application records were evaluated. Of these, 1,749 hold active "Approved" status (677 applications were voluntarily withdrawn over time).
| Application Type | Description | All Species Approved Applications | Companion Animal (Dog/Cat) Approved Applications | Companion Market Share (%) |
|---|---|---|---|---|
| NADA | New Animal Drug Application (Pioneer Brand) | 1,221 | 470 | 72.3% |
| ANADA | Abbreviated New Animal Drug Application (Generic) | 521 | 175 | 26.9% |
| CNADA | Conditionally Approved New Animal Drug Application | 7 | 5 | 0.8% |
| Total | Approved Animal Drug Applications | 1,749 | 650 | 100.0% |
Data source and method: the FDA's publicly downloadable Green Book application, species, active-ingredient, and patent extracts, snapshot dated July 25, 2026. "Companion animal" means any application whose species list includes Dogs or Cats (Domestic), matched on the FDA's own species key rather than on free-text species names, which vary in spelling. Only applications with a status of "Approved" are counted; the 677 voluntarily withdrawn applications are excluded throughout. Anyone can reproduce these counts from the same public files.
2. The 26% Rule: Molecule-Level Availability
While counting total applications shows that roughly 27% of approved companion animal applications are generics, evaluating distinct active ingredients reveals an even starker reality:
- Total Approved Companion Animal Active Ingredients: 261 distinct molecules.
- Molecules with ≥ 1 Approved Generic (ANADA): 69 active ingredients (26.4%).
- Molecules with ZERO Approved Generics: 192 active ingredients (73.6%).
In short: nearly three-quarters of all dog and cat drug molecules approved by the FDA exist exclusively as pioneer brands or single-source products.
How to read this number honestly. An ingredient counts as "having a generic" if any approved companion application containing it is an ANADA. Because combination parasiticides list several actives, a molecule can clear that bar through a product that has nothing to do with the brand a clinic actually buys. Moxidectin is the clearest example: it counts as genericized because of Midamox, IMOXI, and PARASEDGE Multi (all imidacloprid–moxidectin topicals), while ProHeart 6, ProHeart 12, and the moxidectin component of Simparica TRIO have no generic at all. Read the molecule-level figure as an upper bound on genuine substitutability, not a floor.
Most Genericized vs. Zero-Generic Companion Animal Molecules
Generic applications in veterinary medicine are not spread evenly across all therapeutic classes. Instead, generic sponsors heavily target high-volume, legacy small-molecule drugs whose patents expired decades ago.
Top 9 Most Genericized Dog and Cat Molecules
The table below lists the companion animal active ingredients with the highest number of FDA-approved generic applications (ANADAs):
| Active Ingredient | Primary Clinical Indications | Approved ANADAs (Generics) | Approved NADAs (Pioneers) | Notable Pioneer & Generic Examples |
|---|---|---|---|---|
| Carprofen | Osteoarthritis pain & post-op inflammation in dogs | 19 | 3 | Pioneer: Rimadyl caplets, chewables, and sterile injectable (Zoetis). The cleanest true generic market in companion medicine. |
| Enrofloxacin | Fluoroquinolone antibiotic for dogs & cats | 13 | 3 | Pioneer: Baytril tablets, otic, and injectable (Elanco). |
| Meloxicam | NSAID for canine osteoarthritis & feline surgical pain | 11 | 3 | Pioneer: Metacam (Boehringer Ingelheim). Generics include Loxicom and multiple oral suspensions. |
| Moxidectin | Heartworm & endoparasite preventive | 10 | 11 | Pioneers include ProHeart 6/12, Advantage Multi, CORAXIS, and the moxidectin component of Simparica TRIO, BRAVECTO PLUS, NexGard PLUS, and Credelio Quattro. Generics are all imidacloprid–moxidectin topicals (Midamox, IMOXI, PARASEDGE Multi, Barrier, MoxiCloprid). |
| Imidacloprid | Topical flea adulticide (in combination products) | 10 | 4 | Green Book pioneers are Advantage Multi for dogs and cats, Advantage DUO, and advantus (Elanco). Note that single-ingredient topical Advantage is an EPA-registered pesticide, not an FDA-approved animal drug, so it does not appear here. |
| Gentamicin Sulfate | Otic, ophthalmic & topical aminoglycoside | 8 | 11 | Pioneers are the Gentocin family plus Otomax, Mometamax, Topagen, and Easotic (Intervet/Virbac). |
| Clindamycin HCl | Lincosamide antibiotic for dental & skin infections | 6 | 2 | Pioneers: Antirobe Capsules and Antirobe Aquadrops (Zoetis). Generics: Clintabs, Clinsol, and several capsule/oral-liquid lines. |
| Isoflurane | Inhalant anesthetic | 6 | 0 | Unusual case: every approved companion isoflurane application in the Green Book is an ANADA, including IsoFlo (Zoetis), ATTANE, Isospire (Dechra), and ANIRANE (Baxter). There is no surviving approved pioneer NADA for the molecule in dogs or cats. |
| Pyrantel Pamoate | Nematode dewormer (roundworms/hookworms) | 6 | 13 | Pioneer: Nemex-2 (Zoetis), plus a long tail of combination pioneers (Drontal Plus, Heartgard Plus, IVERHART MAX, Virbantel, Simparica TRIO, NexGard PLUS, Credelio Quattro). |
High-Spend Molecules with ZERO Approved Generics
Conversely, many of the most commercially successful and frequently prescribed medications in modern veterinary practice have zero approved ANADAs:
All patent expirations below are the latest patent listed against that application in the Green Book patents table, not a market-exclusivity forecast:
| Brand Name | Active Ingredient | Primary Indication | Approved NADAs | Approved ANADAs | Latest Listed Green Book Patent Expiration |
|---|---|---|---|---|---|
| Apoquel | Oclacitinib | Allergic dermatitis & pruritus in dogs | 2 | 0 | 2033-07-18 (Tablets, NADA 141-345); 2041-09-29 (Chewable, NADA 141-555) |
| Galliprant | Grapiprant | Osteoarthritis pain in dogs (EP4 CRA) | 1 | 0 | 2035-03-05 |
| Librela | Bedinvetmab | Anti-NGF monoclonal antibody for canine OA | 1 | 0 | No patents listed in the Green Book. Librela is an FDA CVM–approved new animal drug (NADA 141-562), not a USDA-licensed biologic — the barrier is the absence of a veterinary biosimilar pathway, not a listed patent |
| Solensia | Frunevetmab | Anti-NGF monoclonal antibody for feline OA | 1 | 0 | 2032-05-08 |
| Simparica / Trio | Sarolaner (+ moxidectin/pyrantel) | Isoxazoline flea, tick, heartworm preventive | 3 | 0 | 2033-08-28 (Simparica, Revolution PLUS); 2041-02-22 (Simparica TRIO) |
| Bravecto | Fluralaner | Isoxazoline flea & tick oral/topical | 5 | 0 | 2035-02-05 (oral, NADA 141-426); 2031-12-22 (topical, NADA 141-459); 2040-01-30 (Quantum, NADA 141-599) |
| NexGard / Plus | Afoxolaner | Isoxazoline flea & tick preventive | 2 | 0 | 2033-01-31 |
| Credelio / Quattro | Lotilaner | Isoxazoline flea & tick preventive | 4 | 0 | 2041-07-22 (Credelio); 2042-05-04 (Credelio Quattro) |
| Vetoryl | Trilostane | Hyperadrenocorticism (Cushing's) in dogs | 1 | 0 | 2024-07-03 — already expired. Both exclusivity periods lapsed in 2013 and 2015. Nothing legal blocks a generic here; the barrier is formulation and market size |
| Palladia | Toceranib phosphate | Receptor tyrosine kinase inhibitor for MCT | 1 | 0 | 2027-07-07 — still live, contrary to the common claim that Palladia is off patent. Exclusivity expired in 2014 |
| Semintra | Telmisartan | Feline hypertension & proteinuria | 1 | 0 | 2030-05-19 |
| Mirataz | Mirtazapine transdermal | Transdermal appetite stimulant for cats | 1 | 0 | 2036-09-13 |
| Zenrelia | Ilunocitinib | JAK inhibitor for allergic pruritus | 1 | 0 | 2040-04-22 |
Two entries in that table are worth pausing on, because they are where the usual "it's under patent" explanation breaks down. Vetoryl's last listed patent expired in July 2024 and its exclusivity lapsed a decade earlier — trilostane is legally open, and no one has filed. Palladia's exclusivity expired in 2014, but a listed patent still runs to July 2027, so the widely repeated claim that toceranib is patent-free today is wrong. When a molecule is legally clear and still has no generic, the binding constraint is economics or formulation difficulty, not intellectual property — and that distinction changes how long a practice should expect to wait.
Why Top Brands Lack Generics: Patents, Exclusivities, and Market Size
Why haven't generic manufacturers created cheaper alternatives for drugs like Apoquel or Bravecto? Three structural barriers explain the gap:
1. Long Patent Thickets and Formulation Exclusivities
Pioneer pharmaceutical companies construct overlapping patent portfolios covering not only the active molecule itself, but also specific salt forms, crystalline polymorphs, chewable flavor matrices, dosing schedules, and manufacturing processes.
For example, while basic active ingredient patents may expire, secondary patents on chewable formulations (such as Apoquel Chewable or Bravecto Quantum) extend protection into the late 2030s and 2040s.
2. Biologicals vs. Small Molecules
Monoclonal antibodies like bedinvetmab (Librela) and frunevetmab (Solensia) are complex biological proteins. Under current regulatory frameworks, there is no standardized "biosimilar" pathway for veterinary monoclonal antibodies comparable to the human biosimilar pathway under the BPCI Act. Developing and manufacturing a biosimilar protein requires massive capital investment, making generic entry cost-prohibitive.
3. Market Size and Return on Investment (ROI)
Developing an ANADA requires $1 million to $3 million in analytical chemistry, stability testing, bioequivalence studies, and FDA filing fees. In human medicine, a blockbuster drug represents tens of billions in annual revenue. In veterinary medicine, a major drug might represent $100 million to $300 million in domestic sales. For smaller niche markets (such as toceranib for canine mast cell tumors), the total market size is insufficient to justify the cost of ANADA development for multiple competitors.
Essential Nuances: What Clinic Teams Must Understand
When evaluating Green Book data and making formulary decisions, three critical nuances prevent common misconceptions:
1. publish_date Is NOT an Approval Date
A common mistake when reading FDA Green Book extracts is assuming the publish_date column represents the original FDA approval date.
The Green Book database contains no original approval date column in its application records. The publish_date field reflects when the digital record was last refreshed or published in the online listing. For example, the FDA approved the first generic pimobendan (Pimomedin) on April 25, 2024 (via FDA CVM Update), but its Green Book publish_date entry reads 2026-05-12. Original approval dates must always be cross-referenced against official FDA CVM Updates or the Animal Drugs @ FDA portal.
2. Approved Is NOT the Same as Available: The Pimobendan Case
Gaining FDA approval is a regulatory milestone, not a commercial launch. Patent litigation, manufacturing scale-up, supply chain setup, and distribution agreements often delay commercial availability by months or years.
- Case Study: On April 25, 2024, the FDA approved Pimomedin (ANADA #200-728, sponsored by Cronus Pharma Specialities India Private Ltd.), the first generic pimobendan chewable tablet for canine congestive heart failure, referencing Vetmedin (NADA #141-273, Boehringer Ingelheim). It is supplied in 1.25, 2.5, 5, and 10 mg oblong half-scored chewable tablets.
- Market Availability: Despite approval in April 2024, the product did not become purchasable through U.S. veterinary distributors until June 9, 2026 — a gap of just over two years between regulatory approval and real-world clinic availability. For clinical context on heart failure management, see our monograph on pimobendan (Vetmedin) for dogs.
- The name changed between approval and launch. FDA approved it as Pimomedin; Cronus brought it to market as plain Pimobendan Chewable Tablets, which is also the proprietary name now carried in the Green Book. If you search a distributor catalogue for the approval-era brand name you will not find it. Search the ANADA number instead.
- Only one strength was tested in live dogs. The 5 mg chewable was the in vivo bioequivalence comparator against 5 mg Vetmedin; the 1.25, 2.5, and 10 mg strengths were approved on comparative dissolution data under a biowaiver. This is normal and permitted, but it is the level of detail a medical director should know before assuming every strength was independently proven in a patient.
3. Generic Status Attaches to a Dosage Form, Not a Molecule
A molecule does not become "generic" in all its forms simultaneously. ANADA approvals are granted specifically per physical dosage form and concentration.
[Maropitant Citrate Molecule]
│
┌─────────────────────────────────┼─────────────────────────────────┐
│ │ │
[Injectable Solution] [Oral Tablets] [Chewable Tablets]
ANADA #200710 (Dechra) ANADA #200747 (ZyVet) ANADA #200833 (Felix)
ANADA #200785 (Felix)
- Example — Maropitant: Maropitant citrate has four approved generic ANADAs across three distinct dosage forms: injectable solution (ANADA #200710 by Dechra), tablets (ANADA #200747 by ZyVet; ANADA #200785 by Felix), and chewable tablets (ANADA #200833 by Felix). Meanwhile, certain pioneer injectable applications still carried listed patents into 2027. This demonstrates that a live patent listing on one application does not necessarily prevent generic approval of another dosage form. For dosage form details, see our review of maropitant (Cerenia) for dogs and cats.
- Example — Cefovecin: Cefovecin sodium currently has exactly one approved generic (ANADA #200812, a lyophilized powder for injection), making it a single-source generic market. For clinical use cases, see our guide on cefovecin (Convenia) injection.
- Example — Robenacoxib: The molecule now has two approved generics across two forms — the injectable solution (ANADA #200804, Cronus Pharma), which the FDA announced on March 9, 2026 as the first generic robenacoxib injectable referencing Onsior injection, and a 6 mg tablet (ANADA #200832, ZyVet). Three Onsior pioneer applications remain. A clinic that switched only its injectable line and assumed the tablets followed would be wrong. See our guide on robenacoxib (Onsior) in dogs and cats.
- Example — Methimazole: Feline hyperthyroidism treatment features generics across two distinct forms: coated tablets (ANADA #200814) and oral solution (ANADA #200771), expanding administration options for cat owners. See our monograph on methimazole for cats.
The Extra-Label Trap: Human Generics vs. Veterinary Generics
A frequent source of confusion in veterinary practice is the distinction between a veterinary generic (ANADA) and a human generic (ANDA) used extra-label.
[Prescribing a Generic Drug]
│
Does an FDA-Approved Animal Drug (NADA/ANADA) Exist?
┌──────────────────┴──────────────────┐
YES NO
│ │
[Veterinary Generic (ANADA)] [Extra-Label Human Generic]
• FDA-tested bioequivalence in target species • Prescribed under AMDUCA rules
• Exact animal labeling & dosing • Human ANDA product
• e.g., Carprofen caplets, Maropitant inj. • e.g., Gabapentin, Trazodone
Many widely prescribed medications in veterinary clinics have no approved animal drug application of any type (neither NADA, ANADA, nor CNADA) in the FDA Green Book:
- Gabapentin: Zero animal drug approvals in the Green Book. All gabapentin dispensed in veterinary clinics consists of human FDA-approved ANDA generic products used extra-label under the Animal Medicinal Drug Use Clarification Act (AMDUCA).
- Trazodone: Zero animal drug approvals in the Green Book. Prescribed as human extra-label generic tablets.
- Levetiracetam: Zero animal drug approvals in the Green Book. Prescribed as human extra-label generic tablets/oral solution.
The Conditional Approval (CNADA) Middle Ground
Phenobarbital represents a unique third category: it holds one conditional approval (CNADA #141-578, FIDOQUEL-CA1 by Genus Lifesciences) and zero full NADA or ANADA approvals. Because a conditionally approved drug (CNADA) has demonstrated safety but is still completing full efficacy trials, it cannot serve as a Reference Listed New Animal Drug for an ANADA generic filing.
Bioequivalence vs. Therapeutic Equivalence
As the Merck Veterinary Manual emphasizes, bioequivalence does not automatically equal therapeutic equivalence in every clinical scenario. Furthermore, under FDA Guidance for Industry (GFI #35 and #171), in vivo bioequivalence studies can be waived (biowaivers) for true solution formulations (such as injectable or oral solutions). Clinic teams switching from a brand to a generic solution should recognize that the approval was granted based on chemical solution equivalence rather than a live-animal bioequivalence trial.
For guidance on navigating drug backorders and therapeutic substitutions, see our veterinary drug shortage substitution playbook. To understand how approved generics differ from compounded preparations, consult our guide on veterinary compounding pharmacy selection under FDA GFI 256.
Sponsor Concentration in Veterinary Generics
Unlike human generics, where giant multinational generic manufacturers (such as Teva, Viatris, or Sandoz) dominate, companion animal generics are produced by a concentrated group of specialized animal health companies.
In the July 2026 Green Book dataset, approved companion animal ANADAs are heavily concentrated among a handful of specialist sponsors:
| Sponsor | Approved companion ANADAs | Share of all 175 |
|---|---|---|
| Cronus Pharma Specialities India | 24 | 13.7% |
| Dechra Veterinary Products | 24 | 13.7% |
| Felix Pharmaceuticals | 23 | 13.1% |
| ZyVet Animal Health | 13 | 7.4% |
| Norbrook Laboratories | 12 | 6.9% |
| Virbac AH | 11 | 6.3% |
| Bimeda Animal Health | 8 | 4.6% |
| Top six combined | 107 | 61.1% |
Six sponsors hold 61% of every approved generic dog and cat drug application in the United States, and the top three alone hold 40%. That concentration is the practical reason a veterinary generic rarely delivers the 80–90% price collapse familiar from human pharmacy: with one to three suppliers per molecule, there is no price war to trigger. It is also a supply-chain risk worth naming — a manufacturing interruption at a single sponsor can take a whole generic line off the shelf, with no second generic to switch to.
Formulary Decision Rules for Practice Owners
For practice owners, medical directors, and inventory managers, moving a formulary line from a pioneer brand to an approved generic requires a structured evaluation:
- Verify ANADA Status: Confirm the product is a true FDA-approved ANADA (carrying an ANADA 200-XXX number) rather than an unapproved compounded preparation.
- Evaluate Dosage Form Match: Ensure the generic matches the exact dosage form used by your patient population (e.g., chewable tablet vs. unflavored caplet).
- Compare Acquisition Cost vs. Margin: Calculate true cost per dose. Switching a high-volume NSAID like carprofen can reduce clinic acquisition costs by 40% to 60%, allowing the practice to lower client prices while preserving dispensing margins. For pricing methodology, see our guide on veterinary pricing strategy and dispensing fees.
- Audit Distributor Stocking & Reliability: Verify that your primary distributor maintains stable inventory levels for the generic line before phasing out the pioneer brand. Practice management software can automate reorder thresholds during a formulary transition—see our review of veterinary inventory management software.
Frequently Asked Questions
Are generic pet medications as effective as brand-name ones?
Yes. An FDA-approved generic animal drug (ANADA) contains the identical active ingredient at the same concentration and dosage form as the pioneer drug. It must prove bioequivalence to the pioneer reference drug and meet strict FDA manufacturing, purity, and stability standards.
Is there a generic version of Apoquel?
No. There are currently zero FDA-approved generic versions of Apoquel (oclacitinib). The pioneer manufacturer (Zoetis) holds patents and exclusivities on oclacitinib formulations extending into 2033 (tablets) and 2041 (chewable tablets).
When will Simparica Trio or Bravecto go generic?
Isoxazoline parasiticides (Simparica Trio, Bravecto, NexGard, Credelio) are protected by extensive patent thickets covering active molecules, combination combinations, and long-acting chewable matrices. Listed Green Book patent expirations for these products extend from 2033 to 2042. Generic versions are not expected on the U.S. market until the mid-2030s at the earliest.
Why is my dog's generic medication still expensive?
Unlike human generic markets where dozens of manufacturers compete to drive prices down by 90%, veterinary generic markets often feature only 1 to 3 generic sponsors. Limited competition, smaller overall market volumes, and specialized manufacturing keep veterinary generic prices higher than human generic equivalents.
Is a human generic of the same drug the same thing as a veterinary generic?
No. A human generic (approved via an ANDA) is tested for human bioequivalence and manufactured in human-oriented strengths and dosage forms. A veterinary generic (approved via an ANADA) is specifically tested and approved for animal species, with animal-appropriate dosing, flavorings, and target-animal safety reviews. Prescribing a human generic to a pet is considered extra-label drug use under AMDUCA.
How can I check whether a specific animal drug has an approved generic?
You can search the FDA Green Book database online or look up the drug in the Animal Drugs @ FDA portal. Look for an ANADA number (a 6-digit number starting with 200-XXX). If a product lists an NADA number (100-XXX or 140-XXX), it is a pioneer drug; an ANADA number indicates an approved generic.
Sources
- U.S. Food and Drug Administration (FDA) CVM: Abbreviated New Animal Drug Applications (ANADA). https://www.fda.gov/animal-veterinary/development-approval-process/abbreviated-new-animal-drug-applications
- U.S. Food and Drug Administration (FDA) CVM: Generic Animal Drug and Patent Term Restoration Act (GADPTRA). https://www.fda.gov/animal-veterinary/guidance-regulations/generic-animal-drug-and-patent-term-restoration-act-gadptra
- U.S. Food and Drug Administration (FDA) CVM: Generic Animal Drugs: Approved or Unapproved? https://www.fda.gov/animal-veterinary/unapproved-animal-drugs/generic-animal-drugs-approved-or-unapproved
- U.S. Food and Drug Administration (FDA) CVM: Approved Animal Drug Products (Green Book) (Snapshot July 25, 2026). https://www.fda.gov/animal-veterinary/products/approved-animal-drug-products-green-book
- U.S. Food and Drug Administration (FDA) CVM Update: FDA Approves First Generic Pimobendan for Management of Congestive Heart Failure in Dogs (April 25, 2024). https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-generic-pimobendan-management-congestive-heart-failure-dogs
- U.S. Food and Drug Administration (FDA) CVM Update: FDA Approves First Generic Robenacoxib Injectable for Postoperative Pain and Inflammation in Dogs and Cats (March 9, 2026). https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-generic-robenacoxib-injectable-postoperative-pain-and-inflammation-dogs-and-cats
- Merck Veterinary Manual (Professional): New Animal Drugs, Extralabel Drug Use, Compounded Drugs, and Generic Drugs. https://www.merckvetmanual.com/pharmacology/pharmacology-introduction/new-animal-drugs-extralabel-drug-use-compounded-drugs-and-generic-drugs
- American Association of Veterinary Pharmacology and Therapeutics (AAVPT): Hendricks IS. Bioequivalence Waivers (Biowaivers), Division of Generic Animal Drugs. https://cdn.ymaws.com/www.aavpt.org/resource/resmgr/imported/17Hendricks.pdf
- Generic Animal Drug Alliance (GADA): About Animal Generics: Generic Animal Drugs Proven Safe and Effective. https://www.gadaonline.org/animalgenerics/safety.cfm
- dvm360: Generic drug is launched on the veterinary market for canine congestive heart failure (June 9, 2026). https://www.dvm360.com/view/generic-drug-is-launched-on-the-veterinary-market-for-canine-congestive-heart-failure
- AVMA JAVMA News: The slow rise of generic animal drugs (July 1, 2016). https://www.avma.org/javma-news/2016-07-01/slow-rise-generic-animal-drugs
